CompletedPhase 2NCT00401128
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
Studying Clear cell papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Cleveland Clinic
- Principal Investigator
- Ronald M. Bukowski, MDThe Cleveland Clinic
- Intervention
- gemcitabine hydrochloride(drug)
- Enrollment
- 9 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2004 – 2007
Study locations (1)
- Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00401128 on ClinicalTrials.govOther trials for Clear cell papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT05665361Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)National Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05287945Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell CarcinomaOncorena AB
- RECRUITINGPHASE1NCT05433142Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05122546CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerCity of Hope Medical Center
See all trials for Clear cell papillary renal cell carcinoma →